Annexin Pharmaceuticals AB (publ) (STO:ANNX)
Sweden flag Sweden · Delayed Price · Currency is SEK
14.50
+0.20 (1.40%)
At close: Mar 6, 2026

STO:ANNX Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Selling, General & Admin
10.079.598.0112.2910.7
Upgrade
Research & Development
26.2440.8136.0328.3742.13
Upgrade
Operating Expenses
36.3150.444.0440.6652.83
Upgrade
Operating Income
-36.31-50.4-44.04-40.66-52.83
Upgrade
Interest Expense
----0-1.86
Upgrade
Interest & Investment Income
0.470.230.12--
Upgrade
Earnings From Equity Investments
----0.95
Upgrade
Currency Exchange Gain (Loss)
-1.05-0.08-0.14-0.071.59
Upgrade
Other Non Operating Income (Expenses)
--0---
Upgrade
Pretax Income
-36.89-50.25-44.05-40.73-52.14
Upgrade
Net Income
-36.89-50.25-44.05-40.73-52.14
Upgrade
Net Income to Common
-36.89-50.25-44.05-40.73-52.14
Upgrade
Shares Outstanding (Basic)
75211
Upgrade
Shares Outstanding (Diluted)
75211
Upgrade
Shares Change (YoY)
46.31%170.59%14.23%78.30%33.40%
Upgrade
EPS (Basic)
-5.58-11.11-26.36-27.84-63.55
Upgrade
EPS (Diluted)
-5.58-11.11-26.36-27.84-63.55
Upgrade
Free Cash Flow
-37.05-50.23-43.4-41.17-45.02
Upgrade
Free Cash Flow Per Share
-5.60-11.11-25.97-28.14-54.88
Upgrade
EBITDA
-36.12-50.2-43.85-40.46-52.63
Upgrade
D&A For EBITDA
0.190.190.190.190.19
Upgrade
EBIT
-36.31-50.4-44.04-40.66-52.83
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.